Valuation, from the filing
| Public float | $6.00B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $106.51 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 122.7× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 8.1× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 2.8× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
122.7× earnings today, against a median of 94.5× across 9 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $6.00B | 122.7× | |
| 2023-06-30 | $6.93B | 194.7× | |
| 2022-06-30 | $8.91B | 47.9× | |
| 2021-06-30 | $10.86B | 84.6× | |
| 2020-06-30 | $5.71B | 95.3× | |
| 2019-06-28 | $3.60B | 168.1× | |
| 2018-06-29 | $1.57B | 94.5× | |
| 2017-06-30 | $1.23B | 43.2× | |
| 2016-06-30 | $915.06M | 78.3× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| R&D / revenue | 7.3% | 5th | |
| SBC / revenue | 4.4% | 11th | |
| FCF margin | 12.7% | 88th | |
| Operating margin | 7.5% | 85th | |
| Net margin | 6.6% | 82th | |
| Current ratio | 8.37x | 72th | |
| Effective tax rate | 21.6% | 71th | |
| Gross margin | 52.3% | 34th | |
| Long-term debt / equity | 0.26x | 38th | |
| Revenue YoY growth | 16.4% | 57th | |
| CapEx / revenue | 3.2% | 45th |
REPLIGEN CORP (RGEN) reported revenue of $805.61M and net income of -$11.80M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from REPLIGEN CORP’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2026-09-30 |
|---|---|
| Revenue | $805.61M |
| Cost of revenue | $374.94M |
| Gross profit | $430.67M |
| Operating income | $18.24M |
| Net income | -$11.80M |
| Research & development | $57.23M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $8.23M |
| Income tax expense | $20.03M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $311.98M |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-09-30 |
|---|---|
| Cash & equivalents | $726.96M |
| Total assets | $2.93B |
| Current assets | $1.24B |
| Total liabilities | $834.67M |
| Current liabilities | $125.69M |
| Total equity incl. NCI | $2.09B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $182.20M |
| Accounts receivable | $151.24M |
| Goodwill | $1.10B |
| Long-term debt | $555.60M |
| Accounts payable | $27.70M |
Cash flow
| Metric | 2026-09-30 |
|---|---|
| Operating cash flow | $129.86M |
| Capital expenditures | $23.14M |
| Investing cash flow | -$150.83M |
| Financing cash flow | $3.06M |
| Net change in cash | -$19.74M |
| Stock-based compensation | $33.67M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $77.90M |
Derived
| Metric | 2026-09-30 |
|---|---|
| Free cash flow | $106.72M |
| Gross margin | 53.5% |
| Operating margin | 2.3% |
| FCF margin | 13.2% |
| SBC / revenue | 4.2% |
| Current ratio | 9.88x |
| Revenue YoY growth | 13.8% |
| Net margin | -1.5% |
| R&D / revenue | 7.1% |
| CapEx / revenue | 2.9% |
| Long-term debt / equity | 0.27x |
| Effective tax rate | 243.4% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RGEN in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.